Viking Therapeutics shares are trading higher after JP Morgan initiated coverage on the stock with an Overweight rating and an $80 price target.
Portfolio Pulse from Benzinga Newsdesk
Viking Therapeutics shares rose following JP Morgan's initiation of coverage with an Overweight rating and an $80 price target.
September 11, 2024 | 12:58 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JP Morgan's initiation of coverage on Viking Therapeutics with an Overweight rating and an $80 price target has led to a rise in the company's stock price.
The Overweight rating and high price target from a major financial institution like JP Morgan is a strong positive signal for investors, likely leading to increased buying interest and a rise in stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100